ArticleJournal of translational medicine2024
Landscapes of gut bacterial and fecal metabolic signatures and their relationship in severe preeclampsia.
Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Untargeted metabolomics for the early detection of preeclampsia: A systematic review of human studies.PloS one · 2026Pooled it
- Exploring the research progression and evolutionary trends of gut microbiome and hypertension: a bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Gut microbiome and pregnancy complications: emerging evidence and mechanistic insights.Gut microbes · 2026Review
- Role of microbial metabolites in the pathogenesis of hypertensive disorders of pregnancy: From short‑chain fatty acids to tryptophan metabolites (Review).Molecular medicine reports · 2026Review
- Maternal and infant gut microbiome.iMeta · 2026Review
- Identifying biomarkers of the serum proteins and metabolites associated with severe preeclampsia.BMC pregnancy and childbirth · 2026Article
- Comparative analysis of gut microbiome alterations in early- and late-onset preeclampsia: A case control study.PloS one · 2026Article
- Microbiota Dysbiosis: A Key Modulator in Preeclampsia Pathogenesis and Its Therapeutic Potential.Microorganisms · 2025Review
- Association of placental manganese levels, maternal gut microbiota, and preeclampsia: a tripartite perspective.Frontiers in microbiology · 2025Article
- Unraveling the gut microbiota-SCFAs-cathepsin C pathway in preeclampsia: a novel therapeutic target.Frontiers in immunology · 2025Article
- Gut Microbiota Dysbiosis in Preeclampsia: Mechanisms, Biomarkers, and Probiotic-Based Interventions.Mediators of inflammation · 2025Article
- Unraveling the role of the gut microbiome in pregnancy disorders: insights and implications.Frontiers in cellular and infection microbiology · 2025Review
- The gut-placenta axis in preeclampsia: unraveling the regulatory network and clinical prospects in pathogenesis.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPreeclampsia is a pregnancy-specific disease leading to maternal and perinatal morbidity. Hypertension and inflammation are the main characteristics of preeclampsia. Many factors can lead to hypertension and inflammation, including gut microbiota which plays an important role in hypertension and inflammation in humans. However, alterations to the gut microbiome and fecal metabolome, and their relationships in severe preeclampsia are not well known. This study aims to identify biomarkers significantly associated with severe preeclampsia and provide a knowledge base for treatments regulating the gut microbiome.
methodsIn this study, fecal samples were collected from individuals with severe preeclampsia and healthy controls for shotgun metagenomic sequencing to evaluate changes in gut microbiota composition. Quantitative polymerase chain reaction analysis was used to validate the reliability of our shotgun metagenomic sequencing results. Additionally, untargeted metabolomics analysis was performed to measure fecal metabolome concentrations.
resultsWe identified several Lactobacillaceae that were significantly enriched in the gut of healthy controls, including Limosilactobacillus fermentum, the key biomarker distinguishing severe preeclampsia from healthy controls. Limosilactobacillus fermentum was significantly associated with shifts in KEGG Orthology (KO) genes and KEGG pathways of the gut microbiome in severe preeclampsia, such as flagellar assembly. Untargeted fecal metabolome analysis found that severe preeclampsia had higher concentrations of Phenylpropanoate and Agmatine. Increased concentrations of Phenylpropanoate and Agmatine were associated with the abundance of Limosilactobacillus fermentum. Furthermore, all metabolites with higher abundances in healthy controls were enriched in the arginine and proline metabolism pathway.
conclusionOur research indicates that changes in metabolites, possibly due to the gut microbe Limosilactobacillus fermentum, can contribute to the development of severe preeclampsia. This study provides insights into the interaction between gut microbiome and fecal metabolites and offers a basis for improving severe preeclampsia by modulating the gut microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.